ScholarX: Browsing ScholarWorks

Browsing by Ghesquieres, HerveAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Sort by: In order: Results/Page Authors/Record:

Showing results 1 to 6 of 6

SCIESCOPUS

Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study

Yasenchak, Christopher; Kim, Jeong-A; Hahn, Uwe; Kim, Won-Seog; Fleury, Isabelle; Laribi, Kamel; Bergua Burgues, Juan Miguel; Bouabdallah, Krimo; Forward, Nicholas; Bijou, Fontanet, et al.

ArticleIssue Date2024CitationCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, v.24, pp S490 - S491PublisherCIG MEDIA GROUP, LP

SCIESCOPUS

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

Bartlett, Nancy L.; Hahn, Uwe; Kim, Won-Seog; Fleury, Isabelle; Laribi, Kamel; Bergua, Juan-Miguel; Bouabdallah, Krimo; Forward, Nicholas; Bijou, Fontanet; MacDonald, David, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.9PublisherLippincott Williams and Wilkins

SCIESCOPUS

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

Kim, Jeong A.; Hahn, Uwe; Kim, Won-Seog; Fleury, Isabelle; Laribi, Kamel; Burgues, Juan Miguel Bergua; Bouabdallah, Krimo; Forward, Nick; Bijou, Fontanet; MacDonald, David, et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.17_SUPPL, pp LBA7005 - LBA7005PublisherLIPPINCOTT WILLIAMS & WILKINS

SCIESCOPUS

Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Karimi, Yasmin H.; Thieblemont, Catherine; Ghesquieres, Herve; Cheah, Chan Y.; Clausen, Michael Roost; Cunningham, David; Jurczak, Wojciech; Linton, Kim M.; Hutchings, Martin; Phillips, Tycel, et al.

ArticleIssue Date2024CitationCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, v.24, pp S461 - S462PublisherCIG MEDIA GROUP, LP

SCIESCOPUS

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)

Karimi, Yasmin; Thieblemont, Catherine; Ghesquieres, Herve; Cheah, Chan Y.; Clausen, Michael Roost; Cunningham, David; Jurczak, Wojciech; Linton, Kim M.; Hutchings, Martin; Phillips, Tycel Jovelle, et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS

SCIESCOPUS

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Abramson, Jeremy S; Ku, Matthew; Hertzberg, Mark; Huang, Hui-Qiang; Fox, Christopher P; Zhang, Huilai; Yoon, Dok Hyun; Kim, Won-Seog; Abdulhaq, Haifaa; Townsend, William, et al.

ArticleIssue Date2024CitationThe Lancet, v.404, no.10466, pp 1940 - 1954PublisherElsevier B.V.

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Browsing by Ghesquieres, HerveAuthor

BROWSE